左旋多巴联合卡巴拉汀治疗对帕金森病患者肌强直及多巴转运体的影响

doi:10.3969/j.issn.1671-7171.2018.05.014

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To study the effect of levodopa combined with rivastigmine on myotonia and dopa transporter in patients with Parkinson's disease (PD). 【Methods】 A total of 101 patients with early Parkinson disease treated in our hospital were randomly divided into control group (n=50) and observation group (n=51). Patients in the control group were treated with levodopa, and patients in the control group were treated with levodopa plus rivastigmine in continuous treatment for 6 months. Parkinson's severity, balance function, Parkinson's grade, clinical symptom improvement time, dopamine transporter radiation count and adverse reactions were compared between the two groups. 【Results】After treatment, UP-DRS (UP-DRS) in the observation group was lower than that in the control group (P<0.05); Berg balance score higher than that of the control group (P<0.05); Parkinson's Hoehn-Yahr classification was lower than that of the control group (P<0.05); Myotonic stiffness, resting tremor and bradykinesia were shorter than those in the control group (P<0.05). The ratio of basal ganglia (BG) to occipital lobe (OC) tended to increase, but the incidence of contralateral control group was higher than that before treatment (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). 【Conclusion】 Levodopa combined with rivastigmine can alleviate the symptoms of PD, improve the balance ability of patients and reduce the adverse reactions in patients with Parkinson's disease.

Key words： Levodopa/PD CholinesteraseInhibitors/PD ParkinsonDisease Myotonia

Received: 14 December 2017

PACS:

R742.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Dong-mei
	XIONG Xue-zhi

Cite this article:

ZHU Dong-mei,XIONG Xue-zhi. Effect of Levodopa Combined with Rivastigmine on Myotonia and Dopa Transporter in Patients with Parkinson's Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(5): 876-878.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.05.014 OR http://www.jcr.net.cn/EN/Y2018/V35/I5/876

[1] Ten Harmsen BL, van Rumund A, Aerts MB, et al. Clinical correlates of cerebral white matter abnormalities in patients with Parkinson's disease[J].Parkinsonism Relat Disord,2018,49:28-33.
[2] Maetzler W, Berg D. Parkinson disease in 2017: Changing views after 200 years of Parkinson disease[J]. Nat Rev Neurol,2018, 10(1038): 183.
[3] 刘疏影,陈彪. 帕金森病流行现状[J]. 中国现代神经疾病杂志, 2016, 16(2): 98-101.
[4] Choi H, Koh SH. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease[J]. Expert Opin Drug Metab Toxicol, 2018, 14(1): 83-90.
[5] 丁宏娟,何建成. 复方地黄方对帕金森病左旋多巴毒副反应大鼠酪氨酸羟化酶变化的影响[J]. 中国老年学杂志, 2015, 35(10): 2625-2627.
[6] 李晋,贺敬敬,易蕊等. 左旋多巴/卡比多巴联合恩他卡朋治疗帕金森病的临床研究[J].现代生物医学进展, 2016, 16(3): 504-506.
[7] 张雪红. 乙酰胆碱酶抑制剂类药物联合盐酸美金刚治疗老年痴呆临床疗效[J].中国老年学杂志, 2013, 33(19): 4681-4685.
[8] 吴恒乾,白洁. 多巴胺转运体功能及其与神经精神疾病的相关研究[J].生理科学进展, 2015, 46(4): 317-321.
[9] 罗瑞静,何建成. 左旋多巴对帕金森病大鼠纹状体多巴胺转运体的影响[J]. 医学研究杂志, 2011, 40(4): 40-43.
[10] 过燕萍. 帕金森病多巴胺系统单光子发射计算机断层扫描显像研究进展[J].临床神经病学杂志, 2010, 23(2): 156-157.
[11] Vatsa R, Shukla J, Mittal BR. In-house Preparation and Quality Control of Tc99m TRODAT 1 for Diagnostic Single-photon Emission Computed Tomography/Computed Tomography Imaging in Parkinson's Disease[J]. Indian J Nucl Med. 2017, 32(4): 266-270.
[12] 黄喆慜,左传涛,武猛. 症状前期帕金森病的PET/SPECT功能影像学研究[J]. 中国临床神经科学, 2015, 23(3): 355-358.
[13] 邓强,李映会,覃瑜. 普拉克索联合左旋多巴治疗帕金森病的临床观察[J].中国药房, 2013, 24(4): 347-349.
[14] 叶虹,罗丽霞,李飞,刘清阁.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察[J].中国医药导报, 2014, 11(28): 58-61.
[15] 李振光,李刚,于占彩等.卡巴拉汀对帕金森病认知功能障碍及跌倒的影响[J]. 中华临床医师杂志, 2015, 9(19): 3549-3553.